Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 th Scientific Sessions with Simultaneous Publication in Diabetes Care. Treatment with a ...

Non-valvular atrial fibrillation accounts for 13–26% of acute ischaemic strokes.1 Direct oral anticoagulants (DOACs) are ...

In patients with hypercortisolism and inadequately controlled type 2 diabetes, mifepristone lowered HbA1c levels by about 1.5 ...

CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes.

WILMINGTON, N.C., June 18, 2025 /PRNewswire/ -- Catalyst Clinical Research today proudly announces it has won the Excellence in Clinical Trial Management category in the Fierce CRO Awards by ...

CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes.